CD8A and acute myeloid leukemia: We conducted a study on 88 newly diagnosed AML patients to evaluate the baseline BM CD8+/CD3+ cytotoxic T-lymphocyte (CTL) subset by flow cytometry and its relation to standard prognostic factors, response to induction therapy, and disease outcome.